Recursion: CDK7 Inhibitor Differentiation Is Initially Paying Off
Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced ...
Zacks Investment Research on MSN2h
Recursion Pharmaceuticals (RXRX) Laps the Stock Market: Here's Why
The most recent trading session ended with Recursion Pharmaceuticals (RXRX) standing at $8.50, reflecting a +1.92% shift from the previouse trading day's closing. The stock outperformed the S&P 500, ...
Zacks Investment Research on MSN15h
Recursion Pharmaceuticals (RXRX) Stock Jumps 8.9%: Will It Continue to Soar?
Recursion Pharmaceuticals (RXRX) shares ended the last trading session 8.9% higher at $8.34. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...